RxDoctor Payments Data

Tina Mathews, MD

Internal Medicine · Yonkers, NYNPI 1073768404

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 53 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196
  • Amgen$120
  • GSK$117
  • Indivior Inc.$112
  • Astellas Pharma US Inc$100
  • Dexcom, Inc.$78
  • plus $380 from 15 others

What the payments were for

  • Food & beverage$98890%
  • Education$11410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,102 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$180,528
Medicare patients
292
Services billed
1,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin155$170,499
OzempicSemaglutide89$108,802
EliquisApixaban110$102,320
Humira PenAdalimumab12$81,693
TrulicityDulaglutide67$79,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$66,127
FarxigaDapagliflozin Propanediol47$51,465
XareltoRivaroxaban29$30,711
EntrestoSacubitril/Valsartan31$26,715
JanumetSitagliptin Phos/Metformin Hcl21$24,766
TradjentaLinagliptin29$21,198
GemtesaVibegron23$19,705
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$15,346
KerendiaFinerenone15$14,841
LinzessLinaclotide23$13,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$108,80289 claims
PfizerEliquis$29$102,320110 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$117$83,695122 claims
Lilly USA, LLCTrulicity$39$79,21767 claims
MerckJanumet, Janumet Xr$16$33,82632 claims
Johnson & JohnsonXarelto$13$30,71129 claims
NovartisEntresto$61$26,71531 claims
AbbVieLinzess, Synthroid$196$15,78858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →